Small Bowel Transplantation

Indications & Contraindications - Gutless No More!

Indications (Irreversible Intestinal Failure):

• Short Bowel Syndrome (SBS) - most common
  • Vascular catastrophe (e.g., midgut volvulus, mesenteric thrombosis)
  • Extensive Crohn's disease
  • Trauma
• Intestinal dysmotility disorders
  • Chronic Intestinal Pseudo-obstruction (CIPO)
• Congenital mucosal disorders (e.g., microvillus inclusion disease)
• Recurrent TPN-related complications:
  • Progressive liver disease (TPN-associated cholestasis)
  • Recurrent central line sepsis (≥2/year or fungal)
  • Loss of venous access (≥2 major sites)
  • Severe dehydration/electrolyte imbalance despite TPN

Contraindications:

• Absolute:
  • Active untreatable malignancy
  • Severe systemic infection (active sepsis)
  • Advanced irreversible multi-organ failure (severe cardiac/pulmonary/hepatic dysfunction not part of IF)
  • Active substance abuse, severe psychiatric illness, non-compliance
• Relative:
  • HIV infection (case-by-case)
  • Advanced age (>60-65 years, physiological age more important)
  • Significant comorbidities

⭐ Most common indication for SBTx is Short Bowel Syndrome (SBS) secondary to vascular catastrophe in adults, and gastroschisis/intestinal atresia in children.

📌 Mnemonic for TPN complications leading to SBTx: LIVER

• Liver disease (TPN-cholestasis)
• Infections (recurrent line sepsis)
• Venous access loss
• Electrolyte/fluid imbalance (severe)
• Renal impairment (less direct, but can be a factor with fluid issues)

Graft Types, Workup & Surgery - Match & Mend Guts

• Graft Options:
  • Isolated Small Bowel Transplant (ISBTx)
  • Combined Liver-Small Bowel Transplant (LSBTx)
  • Multivisceral Transplant (MVT): Incl. stomach, pancreas, duodenum ± liver/colon.
• Essential Workup:
  • Recipient:
    • Key Indication: Irreversible Intestinal Failure + severe Parenteral Nutrition (PN) Complications (e.g., IFALD, recurrent CVC sepsis, loss of access).
    • Matching: ABO, HLA typing, Panel Reactive Antibody (PRA) screen.
  • Donor:
    • ABO compatibility (identical/compatible).
    • Size matching (critical for abdominal domain). CMV status.
• Surgical Cornerstones:
  • Vascular Anastomoses: Arterial (Aorta/SMA) & Venous (Portal vein).
  • Enteric Reconstruction: Proximal & distal bowel continuity.
  • Graft Monitoring: Ileostomy often created for endoscopic surveillance & biopsy.
  • Perioperative: Induction immunosuppression.

  ⭐ Short Gut Syndrome with Parenteral Nutrition failure is the leading indication for Small Bowel Transplantation (SBTx).

Immunosuppression & Rejection - Immune Peace Talks

• Goal: Prevent host immune destruction of graft.
• Immunosuppression Phases:
  • Induction: Potent, short-term. Anti-thymocyte globulin (ATG), Basiliximab (IL-2R Ab).
  • Maintenance: Long-term triple therapy.
    • Calcineurin Inhibitors (CNIs): Tacrolimus (preferred), Cyclosporine.
    • Antiproliferatives: Mycophenolate Mofetil (MMF), Azathioprine.
    • Corticosteroids: Prednisolone.
  • 📌 Tacro, MMF, Steroids: Three Musketeers Stopping rejection.
• Rejection Types & Management:
  • Hyperacute: Mins-hrs. Pre-formed Ab. Irreversible. Prevent: Crossmatch.
  • Acute Cellular Rejection (ACR): Days-wks. T-cell mediated. Dx: Biopsy. Rx: Steroid pulses; ATG (resistant).

    ⭐ ACR is most common, typically in first few months post-transplant.

  • Antibody-Mediated Rejection (AMR): Donor-Specific Antibodies (DSA). Dx: Biopsy (C4d+), DSA. Rx: Plasmapheresis, IVIG, Rituximab.
  • Chronic Rejection: Months-yrs. Fibrosis, gradual loss. Poor prognosis.
• Small Bowel Specifics:
  • Highly immunogenic (↑Gut-Associated Lymphoid Tissue - GALT).
  • ↑ Rejection & Graft-versus-Host Disease (GVHD) risk.
  • Monitoring: Endoscopy + biopsy, serum citrulline.

Complications & Outcomes - Post-Tx Challenges

• Rejection: Most significant challenge.
  • Acute Cellular Rejection (ACR): Commonest in first year; diagnosed by biopsy. Presents with fever, abdominal pain, ↑stoma output.
  • Chronic Rejection: Leads to fibrosis, dysmotility, malabsorption; major cause of late graft loss.
• Infection: High risk due to potent immunosuppression.
  • Cytomegalovirus (CMV) is very common.
  • Bacterial, fungal, and other viral (e.g., EBV) infections are frequent.
• Post-Transplant Lymphoproliferative Disorder (PTLD):
  • Often EBV-driven; incidence 10-20%.
  • Management: Reduce immunosuppression, rituximab.
• Surgical Complications:
  • Anastomotic leak/stricture, bleeding, vascular thrombosis (arterial/venous).
• Graft-versus-Host Disease (GVHD):
  • Less common than bone marrow transplant but carries high mortality.
• Outcomes:
  • Patient Survival: 1-year ~75-80%; 5-year ~50-60%.
  • Graft Survival: 1-year ~70-75%; 5-year ~40-50%.
  • Successful transplant offers freedom from parenteral nutrition.

⭐ Acute cellular rejection remains the most common cause of graft dysfunction and loss in the first post-operative year for small bowel transplant recipients.

High‑Yield Points - ⚡ Biggest Takeaways

• Key Indication: Short bowel syndrome with IFALD, recurrent line sepsis, or loss of vascular access.
• Transplant Types: Isolated small bowel, combined liver-small bowel, or multivisceral grafts.
• Potent immunosuppression (e.g., tacrolimus) is mandatory.
• Acute cellular rejection is frequent; diagnosed by endoscopic biopsy.
• High risk of CMV infection and PTLD (Post-Transplant Lymphoproliferative Disorder).
• Graft-versus-host disease (GVHD) is a significant concern.
• Regular endoscopic surveillance is crucial for graft monitoring.